These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28040796)

  • 1. Role of RPL39 in Metaplastic Breast Cancer.
    Dave B; Gonzalez DD; Liu ZB; Li X; Wong H; Granados S; Ezzedine NE; Sieglaff DH; Ensor JE; Miller KD; Radovich M; KarinaEtrovic A; Gross SS; Elemento O; Mills GB; Gilcrease MZ; Chang JC
    J Natl Cancer Inst; 2017 Jun; 109(6):. PubMed ID: 28040796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
    Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
    Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockdown of ribosomal protein L39 by RNA interference inhibits the growth of human pancreatic cancer cells in vitro and in vivo.
    Li C; Chen D; Luo M; Ge M; Zhu J
    Biotechnol J; 2014 May; 9(5):652-63. PubMed ID: 24799381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological Inhibition of NOS Activates ASK1/JNK Pathway Augmenting Docetaxel-Mediated Apoptosis in Triple-Negative Breast Cancer.
    Dávila-González D; Choi DS; Rosato RR; Granados-Principal SM; Kuhn JG; Li WF; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
    Clin Cancer Res; 2018 Mar; 24(5):1152-1162. PubMed ID: 29301832
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling.
    Dave B; Granados-Principal S; Zhu R; Benz S; Rabizadeh S; Soon-Shiong P; Yu KD; Shao Z; Li X; Gilcrease M; Lai Z; Chen Y; Huang TH; Shen H; Liu X; Ferrari M; Zhan M; Wong ST; Kumaraswami M; Mittal V; Chen X; Gross SS; Chang JC
    Proc Natl Acad Sci U S A; 2014 Jun; 111(24):8838-43. PubMed ID: 24876273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induced nitric oxide inhibits IL-6-induced stat3 activation and type II acute phase mRNA expression.
    Villavicencio RT; Liu S; Kibbe MR; Williams DL; Ganster RW; Dyer KF; Tweardy DJ; Billiar TR; Pitt BR
    Shock; 2000 Jun; 13(6):441-5. PubMed ID: 10847630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling.
    Jiang HL; Sun HF; Gao SP; Li LD; Hu X; Wu J; Jin W
    Oncotarget; 2015 Jun; 6(18):16352-65. PubMed ID: 25970785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The inhibitory effect of leptin on angiotensin II-induced vasoconstriction in vascular smooth muscle cells is mediated via a nitric oxide-dependent mechanism.
    Rodríguez A; Fortuño A; Gómez-Ambrosi J; Zalba G; Díez J; Frühbeck G
    Endocrinology; 2007 Jan; 148(1):324-31. PubMed ID: 17038553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitric Oxide Inhibitors Hit Target for Triple-Negative Breast Cancer.
    Firger J
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26243205
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer.
    Kung CP; Cottrell KA; Ryu S; Bramel ER; Kladney RD; Bao EA; Freeman EC; Sabloak T; Maggi L; Weber JD
    Oncogene; 2021 Jan; 40(1):189-202. PubMed ID: 33110236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer.
    Chung AW; Anand K; Anselme AC; Chan AA; Gupta N; Venta LA; Schwartz MR; Qian W; Xu Y; Zhang L; Kuhn J; Patel T; Rodriguez AA; Belcheva A; Darcourt J; Ensor J; Bernicker E; Pan PY; Chen SH; Lee DJ; Niravath PA; Chang JC
    Sci Transl Med; 2021 Dec; 13(624):eabj5070. PubMed ID: 34910551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased inducible nitric oxide synthase and arginase II expression in heart failure: no net nitrite/nitrate production and protein S-nitrosylation.
    Heusch P; Aker S; Boengler K; Deindl E; van de Sand A; Klein K; Rassaf T; Konietzka I; Sewell A; Menazza S; Canton M; Heusch G; Di Lisa F; Schulz R
    Am J Physiol Heart Circ Physiol; 2010 Aug; 299(2):H446-53. PubMed ID: 20511413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
    Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
    Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
    Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
    Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling.
    González-González A; Muñoz-Muela E; Marchal JA; Cara FE; Molina MP; Cruz-Lozano M; Jiménez G; Verma A; Ramírez A; Qian W; Chen W; Kozielski AJ; Elemento O; Martín-Salvago MD; Luque RJ; Rosa-Garrido C; Landeira D; Quintana-Romero M; Rosato RR; García MA; Ramirez-Tortosa CL; Kim H; Rodriguez-Aguayo C; Lopez-Berestein G; Sood AK; Lorente JA; Sánchez-Rovira P; Chang JC; Granados-Principal S
    Clin Cancer Res; 2018 Nov; 24(22):5697-5709. PubMed ID: 30012564
    [No Abstract]   [Full Text] [Related]  

  • 16. In vitro effects of nitric oxide synthase inhibitor L-NAME on oral squamous cell carcinoma: a preliminary study.
    Shang ZJ; Li ZB; Li JR
    Int J Oral Maxillofac Surg; 2006 Jun; 35(6):539-43. PubMed ID: 16497478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RSK-mediated down-regulation of PDCD4 is required for proliferation, survival, and migration in a model of triple-negative breast cancer.
    Cuesta R; Holz MK
    Oncotarget; 2016 May; 7(19):27567-83. PubMed ID: 27028868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of Wwox drives metastasis in triple-negative breast cancer by JAK2/STAT3 axis.
    Chang R; Song L; Xu Y; Wu Y; Dai C; Wang X; Sun X; Hou Y; Li W; Zhan X; Zhan L
    Nat Commun; 2018 Aug; 9(1):3486. PubMed ID: 30154439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
    Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
    Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hindlimb ischemia/reperfusion-induced remote injury to the small intestine: role of inducible nitric-oxide synthase-derived nitric oxide.
    Katada K; Bihari A; Badhwar A; Yoshida N; Yoshikawa T; Potter RF; Cepinskas G
    J Pharmacol Exp Ther; 2009 Jun; 329(3):919-27. PubMed ID: 19270191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.